Bristol-Myers Squibb Co. and Pfizer Inc. will present eight of their abstracts at the American College of Cardiology's 66th Annual Scientific Session in Washington, D.C. March 17-19. Read More »

Amgen's results of its Repatha (evolocumab) cardiovascular outcomes trial will be released at the American College of Cardiology's 66th Annual Scientific Session, which is set to take place in Washington, D.C. March 17-19. Read More »

CVS Health has selected Epic as its new electronic health record system for its more specialized care program, CVS Specialty, which includes Accordant, a care management program available to individuals suffering from rare diseases. Read More »

Following a precautionary hold on the dosing of an FAAH inhibitor, Janssen has again begun its clinical research of this investigational medication in two Phase 2 studies.  Read More »

Sandoz, a Novartis division, has released data for its proposed biosimilar adalimumab (GP2017). Read More »

Janssen Research & Development LLC (Janssen) recently announced findings from two Phase 3 studies reporting the efficacy and safety of guselkumab in the treatment of adults with moderate to severe plaque psoriasis. Read More »

In a recent February 2017 study, by Kidney International, found that Proton Pump Inhibitors (PPIs), may cause adverse effects on the human kidney.  Read More »

Immune Pharmaceuticals Inc. will broaden enrollment eligibility criteria for its 10-patient open label study of Bertilimumab in the treatment of Bullous Pemphigoid (BP) after data was compiled from three patients who completed treatment. Read More »

Teva Pharmaceutical Industries Ltd. has launched generic Pristiq 1 (desvenlafaxine) extended-release tablets in 25, 50 and 100 mg in the United States.  Read More »

Walgreens and Piedmont Healthcare recently added Piedmont Healthcare clinical services at 27 retail health clinics in Walgreens throughout Atlanta.  Read More »

Leaders from the health care continuum met last month in Washington, D.C. to explore methods to enhance payment and delivery methods for the private market to create better value for patients. Read More »

Synergy Pharmacy Services recently received its Pharmacy Compounding Accreditation Board accreditation, which classifies it as a company that follows the highest quality and safety standards in the industry. Read More »

Matthew Myers, president of the Campaign for Tobacco-Free Kids, recently applauded CVS Pharmacy stores for its decision to remove tobacco products from its stores and the positive results that have already stemmed from it. Read More »

According to a recent PRNewswire release, CVS Pharmacy is the first national retail pharmacy chain to remove trans fat from their store brand food products.  Read More »

The Pharmaceutical Research and Manufacturers of American (PhRMA) recently sponsored "Through the Microscope: Examining Modern Medicine," its first national health care dialogue series.  Read More »

3M Drug Delivery Systems will continue its collaboration with Panacea Pharmaceuticals Inc., this time working on a new phase in its study of an investigational therapeutic cancer vaccine that would be delivered to the dermis via 3M's Hollow Microstructured Transdermal System. Read More »

CVS Health Research Institute recently released a statement on its decision to stop selling tobacco products and the research behind that decision.  Read More »

Biogen Inc., a global pharmaceutical manufacture, has launched a subsidiary global hemophilia business, Bioverativ. Read More »

Palatin Technologies Inc. has closed its license agreement with AMAG Pharmaceuticals Inc. for the development of Rekynda in North America. Read More »

Portola Pharmaceuticals recently signed a $150 million royalty agreement with HealthCare Royalty Partners for Development and Commercialization of Andexanat Alfa, an antidote for  Factor Xa inhibitors. Read More »